Immunomedics (NASDAQ: IMMU) announced that isactuzumab govitecan (IMMU-132), the Company's proprietary solid-tumor antibody-drug conjugate (ADC), continues to produce encouraging results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE